Logo-jnp
J Nephropathol. 2021;10(2): e10.
doi: 10.34172/jnp.2021.10
  Abstract View: 417
  PDF Download: 254

Min Review

Renal and liver injury following the treatment of COVID-19 by remdesivir

Mohsen Mohammad Rahimi 1 ORCID logo, Elham Jahantabi 2, Behzad Lotfi 3, Mehdi Forouzesh 4, Rohollah Valizadeh 5 ORCID logo, Saman Farshid 6 * ORCID logo

1 Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Urology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
4 Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
5 Student Research Committee, Department of Epidemiology, School of Public Health, Tehran, Iran University of Medical Sciences, Tehran, Iran
6 Department of Urology and Nephrology, Urmia University of Medical Sciences, Urmia, Iran
*Corresponding author: Saman Farshid, Email: farshid.s@umsu.ac.ir

Abstract

Remdesivir initially was intravenously administrated to treat the Ebola disease however right now it has been administered to treat COVID-19 in some countries. However it is necessary to find the exact effect of remdesivir in patients with COVID-19. Remdesivir solution is administered with a cyclodextrin carrier that filters solely by the glomeruli; thereby patients with abnormal renal function cannot eliminate it quickly; therefore, remdesivir can lead to renal failure or liver dysfunction during therapeutic process of COVID-19. Assessment of renal function in patients with COVID-19 who have acute kidney injury (AKI) or end-stage renal disease is fundamental.
Keywords: Remdesivir, COVID-19, Renal injury, Liver injury, Acute kidney injury, End-stage renal disease

Implication for health policy/practice/research/medical education: In the patients taking remdesivir, liver and kidney function tests should be monitored daily, and remdesivir should be held in patients with increased liver enzymes or kidney function impairment.

Please cite this paper as: Rahimi MM, Jahantabi E, Lotfi B, Forouzesh M, Valizadeh R, Farshid S. Renal and liver injury following the treatment of COVID-19 by remdesivir. J Nephropathol. 2021;10(2):e10. DOI: 10.34172/jnp.2021.10.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 417

Your browser does not support the canvas element.


PDF Download: 254

Your browser does not support the canvas element.

Submitted: 20 Jul 2020
Accepted: 28 Aug 2020
ePublished: 30 Aug 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)